UBE3A Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant UBE3A.
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, IF, E |
---|---|
Primary Accession | Q05086 |
Other Accession | BC009271 |
Reactivity | Human, Rat |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 2F6 |
Calculated MW | 100688 Da |
Gene ID | 7337 |
---|---|
Other Names | Ubiquitin-protein ligase E3A, 632-, E6AP ubiquitin-protein ligase, Human papillomavirus E6-associated protein, Oncogenic protein-associated protein E6-AP, Renal carcinoma antigen NY-REN-54, UBE3A, E6AP, EPVE6AP, HPVE6A |
Target/Specificity | UBE3A (AAH09271, 51 a.a. ~ 150 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | UBE3A Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes an E3 ubiquitin-protein ligase, part of the ubiquitin protein degradation system. This imprinted gene is maternally expressed in brain and biallelically expressed in other tissues. Maternally inherited deletion of this gene causes Angelman Syndrome, characterized by severe motor and intellectual retardation, ataxia, hypotonia, epilepsy, absence of speech, and characteristic facies. The protein also interacts with the E6 protein of human papillomavirus types 16 and 18, resulting in ubiquitination and proteolysis of tumor protein p53. Alternative splicing of this gene results in three transcript variants encoding three isoforms with different N-termini. Additional transcript variants have been described, but their full length nature has not been determined.
References
1.The E6 proteins from multiple beta HPV types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation.Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA.J Virol. 2008 Nov;82(21):10408-17. Epub 2008 Aug 20.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.